HOME >> BIOLOGY >> NEWS
Commercialization deal boosts hope for new sickle-cell drug

A novel once-a-day treatment for sickle-cell disease, based on technology developed at Children's Hospital Boston (CHB) and Beth Israel Deaconess Medical Center (BIDMC), has taken an important step toward the clinic. McNeil Consumer & Specialty Pharmaceuticals and Icagen, Inc., a private biotechnology company, have agreed to jointly develop and commercialize the drug, known as ICA-17043. The agreement follows successful Phase II clinical trials in 90 adults with sickle-cell disease. The companies will collaborate on multicenter Phase III trials, the final step before seeking marketing approval from the U.S. Food and Drug Administration.

Current treatment options are few for sickle-cell disease, a genetic blood disorder that affects millions of children and adults worldwide, including about 70,000 Americans, primarily people of African descent (about 8 percent of African-Americans are carriers). The only approved sickle-cell treatment, developed at CHB 20 years ago, is hydroxyurea. Companies have been slow to invest in additional sickle-cell treatments because the potential market is relatively small. The FDA granted ICA-17043 Orphan Drug Designation in 2000 and Fast Track Status in 2002.

ICA-17043 is related to clotrimazole, an antifungal drug approved in 1975 and long used to treat vaginal yeast infections, jock itch, and athlete's foot. A team led by Dr. Carlo Brugnara, director of the Hematology Laboratory at CHB, discovered in the early 1990s that clotrimazole also reduces sickling of red blood cells.

In sickle cell disease, the body produces an abnormal form of hemoglobin, the compound in red blood cells that carries oxygen. The hemoglobin clumps up and polymerizes forms long rod shapes. This polymerization bends the red cells into sickle-shaped structures, and also causes the cell to lose water. This dehydration, in turn, hardens the cells and promotes sickling by hastening polymerization.

"When
'"/>

Contact: Mary-Ellen Shay
mary.shay@childrens.harvard.edu
617-355-6420
Children's Hospital Boston
3-Aug-2004


Page: 1 2 3

Related biology news :

1. EC boosts European electron microscopy research
2. Bioreactor boosts chemical fermentation by 50 percent: study
3. New genomics tool boosts diabetes research
4. DHEA boosts growth rate of human neural stem cells
5. Marine scientists discover nutrient pollution boosts fungi, bacteria killing Caribbean reefs
6. Sleep boosts ability to learn language, University of Chicago researchers find
7. $13 million grant boosts breast cancer research
8. New national studies show combined hormone replacement therapy boosts stroke, dementia
9. Green tea boosts antimicrobial properties of toothpaste
10. Study boosts confidence in potential screening tool for Alzheimers disease
11. Twenty years of monkey research boosts AIDS knowledge

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Commercialization deal boosts hope for new sickle cell drug

(Date:8/21/2014)... BLOOMINGTON, Ind. -- A new study of American ... partner, men have the highest orgasm rates. On ... time, with their sexual orientation making little difference. ... On average, women experience orgasm 62.9 percent of ... -- and this pattern varies with women,s sexual ...
(Date:8/21/2014)... unknown process for harvesting energy and producing oxygen from ... University scientist has discovered. The discovery lays the foundation ... energy from the Sun, and understanding dense blooms like ... worldwide. A paper describing the discovery will be published ... journal Science on 21 August 2014. , ...
(Date:8/21/2014)... to dandruff, eczema and other itchy, flaky maladies in ... reachesincluding Hawaiian coral reefs and the extreme environments of ... in the scientific journal PLOS Pathogens considers ... the genus Malassezia in light of new ... the world. , University of Hawai,i at Mānoa scientist ...
Breaking Biology News(10 mins):Orgasm rates for single women less predictable than men's, vary by sexual orientation 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 4Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2
(Date:8/21/2014)... 21, 2014 DNA vaccine pioneer ... its development of JRC-LAMP-vax, an innovative and safe potential ... IC studies began this month in Hawaii, moving the ... , The Japanese red cedar releases pollen that causes ... Mountain Cedar pollen wreaks similar havoc in Colorado, New ...
(Date:8/21/2014)... August 21, 2014 ... has announced the addition of the  "Global ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... therapy, is a means of replacing hormones ... the body. This type of therapy is ...
(Date:8/21/2014)...  Decision Resources Group finds that the asthma ... Mexico currently faces severe ... agents, the anticipated label extension of Boehringer Ingelheim/Pfizer,s ... emerging biologics will substantially increase the competitiveness of ... inhibitors will introduce a new dynamic to the severe, ...
(Date:8/21/2014)... 21, 2014  Four-dimensional (4-D) printing develops materials ... external stimuli such as changes in temperature. This ... effect in multiple industries.  In the near future, ... printing objects ranging from human organs to parts ... Logo - http://photos.prnewswire.com/prnh/20140820/138289 ...
Breaking Biology Technology:Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4
Cached News: